Your session is about to expire
← Back to Search
Antioxidants for ALS (MICABO-ALS Trial)
MICABO-ALS Trial Summary
This trial is investigating whether giving patients with ALS antioxidants could help slow or stop the progression of the disease. The original trial showed some benefits, so they are expanding it to include higher doses of antioxidants.
- Lou Gehrig's Disease
MICABO-ALS Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.MICABO-ALS Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have been diagnosed with other brain diseases like Parkinson's or Alzheimer's.You have HIV.A doctor has diagnosed you with ALS based on specific criteria.You are between 21 and 80 years old.
Frequently Asked Questions
Could I be a candidate for this experiment?
"The ideal candidate for this study would be someone with amyotrophic lateral sclerosis that falls in the age range of 21 to 80. A total of 60 patients are needed."
Has this method been federally sanctioned?
"This is a Phase 2 trial, which means that while there is some data supporting safety, there is none yet to suggest efficacy. Therefore, our team at Power has estimated the safety of this treatment to be a 2."
Are patients who are 45 years or older able to enroll in this research project?
"The target age group for this clinical trial are adults aged 21 to 80 years old."
How many subjects are included in this trial?
"The trial is currently underway, with the most recent update to the clinicaltrials.gov page occurring on March 25th, 2022. This study seeks 60 participants from a single site."
Are researchers looking for more test subjects at this time?
"The clinicaltrials.gov website has the most up-to-date information on this matter, and it does show that the study is still recruiting patients. This particular trial was first posted on April 1st, 2022 and was last edited on March 25th, of the same year. They are looking for a total of 60 individuals who meet the requirements and are willing to participate in this experiment from one location."
Share this study with friends
Copy Link
Messenger